FibroGen uses its expertise in CTGF and HIF biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company's product, Roxadustat, is an oral small-molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease. FibroGen generates the majority of its revenue in Europe and Japan through collaboration agreements. The company seeks partners with research, development, and marketing capabilities to advance product candidates. FibroGen is headquartered in San Francisco and has subsidiary offices in Beijing and Shanghai.